Department of Pediatric Cardiology, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Trials. 2024 Sep 3;25(1):581. doi: 10.1186/s13063-024-08436-8.
Branch pulmonary artery (PA) stenosis is one of the most common indications for percutaneous interventions in patients with transposition of the great arteries (TGA), tetralogy of Fallot (ToF), and truncus arteriosus (TA). However, the effects of percutaneous branch PA interventions on exercise capacity remains largely unknown. In addition, there is no consensus about the optimal timing of the intervention for asymptomatic patients according to international guidelines. This trial aims to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with TGA, ToF, and TA. In addition, it aims to assess the effects on RV function and to define early markers for RV adaptation and RV dysfunction to improve timing of these interventions.
This is a randomized multicenter interventional trial. TGA, ToF, and TA patients ≥ 8 years with a class IIa indication for percutaneous branch PA intervention according to international guidelines are eligible to participate. Patients will be randomized into the intervention group or the control group (conservative management for 6 months). All patients will undergo transthoracic echocardiography, cardiac magnetic resonance (CMR) imaging, and cardiopulmonary exercise testing at baseline, 6 months, and 2-4 years follow-up. Quality of life (QoL) questionnaires will be obtained at baseline, 2 weeks post intervention or a similar range for the control group, and 6 months follow-up. The primary outcome is exercise capacity expressed as maximum oxygen uptake (peak VO as percentage of predicted). A total of 56 patients (intervention group n = 28, control group n = 28) is required to demonstrate a 14% increase in maximum oxygen uptake (peak VO as percentage of predicted) in the interventional group compared to the control group (power 80%, overall type 1 error controlled at 5%). Secondary outcomes include various parameters for RV systolic function, RV functionality, RV remodeling, procedural success, complications, lung perfusion, and QoL.
This trial will investigate the effects of percutaneous branch PA interventions on exercise capacity in patients with TGA, ToF, and TA and will identify early markers for RV adaptation and RV dysfunction to improve timing of the interventions.
ClinicalTrials.gov NCT05809310. Registered on March 15, 2023.
分支肺动脉(PA)狭窄是大动脉转位(TGA)、法洛四联症(ToF)和动脉干患者经皮介入治疗的最常见适应证之一。然而,经皮分支 PA 介入对运动能力的影响在很大程度上仍不清楚。此外,根据国际指南,对于无症状患者,关于介入的最佳时机尚无共识。本试验旨在确定 TGA、ToF 和 TA 患者经皮分支 PA 狭窄介入对运动能力的影响。此外,它旨在评估对 RV 功能的影响,并确定 RV 适应和 RV 功能障碍的早期标志物,以改善这些干预措施的时机。
这是一项随机多中心介入性试验。符合以下条件的 TGA、ToF 和 TA 患者(年龄≥8 岁)有国际指南 IIa 类适应证进行经皮分支 PA 介入治疗,可入选本试验。患者将随机分为干预组或对照组(保守治疗 6 个月)。所有患者将在基线、6 个月和 2-4 年随访时接受经胸超声心动图、心脏磁共振成像和心肺运动试验。在基线、干预后 2 周或对照组类似时间以及 6 个月随访时获得生活质量(QoL)问卷。主要结局是运动能力,以最大摄氧量(peak VO 占预计值的百分比)表示。需要 56 例患者(干预组 n=28,对照组 n=28),以证明干预组的最大摄氧量(peak VO 占预计值的百分比)比对照组增加 14%(效能 80%,总Ⅰ型错误控制在 5%)。次要结局包括 RV 收缩功能、RV 功能、RV 重塑、手术成功率、并发症、肺灌注和 QoL 的各种参数。
本试验将研究 TGA、ToF 和 TA 患者经皮分支 PA 介入对运动能力的影响,并确定 RV 适应和 RV 功能障碍的早期标志物,以改善干预时机。
ClinicalTrials.gov NCT05809310。于 2023 年 3 月 15 日注册。